Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 17/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 15/20 | 0.74 |
| ▸ | YEATS4 | O95619 | 1/20 | 0.74 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.55 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.55 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11916011 | 0.86 | YEATS4 (1.00) | L3MBTL3L3MBTL1YEATS4ALDH1A1HPGD | |
| SCHEMBL2300134 | 0.84 | YEATS4 (0.97) | L3MBTL3L3MBTL1YEATS4ALDH1A1HPGD | |
| SCHEMBL279856 | 0.82 | L3MBTL3 (0.81) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL27688414 | 0.81 | L3MBTL3 (0.88) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL12529270 | 0.80 | YEATS4 (0.67) | L3MBTL3L3MBTL1YEATS4ALDH1A1HPGD | |
| SCHEMBL12313389 | 0.79 | L3MBTL3 (0.74) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL277178 | 0.79 | L3MBTL3 (0.79) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL14395488 | 0.78 | L3MBTL3 (0.78) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL12265875 | 0.78 | YEATS4 (0.65) | L3MBTL3L3MBTL1YEATS4ALDH1A1HPGD | |
| SCHEMBL12529298 | 0.77 | YEATS4 (0.77) | L3MBTL1YEATS4ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026368-B2 | Hydrazide compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-09-27 | — | — | US | disclosed |
| US-20090253751-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253751-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, THPO, PTAFR | L3MBTL3 3986/4885L3MBTL1 2628/4885YEATS4 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.